Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling

Hitoshi Zembutsu, Yasuyo Suzuki, Aya Sasaki, Tatsuhiko Tsunoda, Minoru Okazaki, Masataka Yoshimoto, Tadashi Hasegawa, Koichi Hirata, Yusuke Nakamura

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy with docetaxel for advanced breast cancer can improve the radicality for a subset of patients, but some patients suffer from severe adverse drug reactions without any benefit. To establish a method for predicting responses to docetaxel, we analyzed gene expression profiles of biopsy materials from 29 advanced breast cancers using a cDNA microarray consisting of 36,864 genes or ESTs, after enrichment of cancer cell population by laser microbeam microdissection. Analyzing eight PR (partial response) patients and twelve patients with SD (stable disease) or PD (progressive disease) response, we identified dozens of genes that were expressed differently between the 'responder (PR)' and 'nonresponder (SD or PD)' groups. We further selected the nine 'predictive' genes showing the most significant differences and established a numerical prediction scoring system that clearly separated the responder group from the non-responder group. This system accurately predicted the drug responses of all of nine additional test cases that were reserved from the original 29 cases. Moreover, we developed a quantitative PCR-based prediction system that could be feasible for routine clinical use. Our results suggest that the sensitivity of an advanced breast cancer to the neoadjuvant chemotherapy with docetaxel could be predicted by expression patterns in this set of genes.

Original languageEnglish
Pages (from-to)361-370
Number of pages10
JournalInternational Journal of Oncology
Volume34
Issue number2
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

docetaxel
Gene Expression Profiling
Genome
Breast Neoplasms
Drug Therapy
Genes
Microdissection
Expressed Sequence Tags
Oligonucleotide Array Sequence Analysis
Drug-Related Side Effects and Adverse Reactions
Transcriptome
Lasers
Biopsy
Polymerase Chain Reaction
Pharmaceutical Preparations
Population

Keywords

  • Breast cancer
  • Docetaxel
  • Gene expression profile
  • Microarray
  • Neoadjuvant chemotherapy
  • Prediction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. / Zembutsu, Hitoshi; Suzuki, Yasuyo; Sasaki, Aya; Tsunoda, Tatsuhiko; Okazaki, Minoru; Yoshimoto, Masataka; Hasegawa, Tadashi; Hirata, Koichi; Nakamura, Yusuke.

In: International Journal of Oncology, Vol. 34, No. 2, 2009, p. 361-370.

Research output: Contribution to journalArticle

Zembutsu, H, Suzuki, Y, Sasaki, A, Tsunoda, T, Okazaki, M, Yoshimoto, M, Hasegawa, T, Hirata, K & Nakamura, Y 2009, 'Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling', International Journal of Oncology, vol. 34, no. 2, pp. 361-370. https://doi.org/10.3892/ijo_00000159
Zembutsu, Hitoshi ; Suzuki, Yasuyo ; Sasaki, Aya ; Tsunoda, Tatsuhiko ; Okazaki, Minoru ; Yoshimoto, Masataka ; Hasegawa, Tadashi ; Hirata, Koichi ; Nakamura, Yusuke. / Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. In: International Journal of Oncology. 2009 ; Vol. 34, No. 2. pp. 361-370.
@article{ba21f46958814c8bb559d9c6c23aab30,
title = "Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling",
abstract = "Neoadjuvant chemotherapy with docetaxel for advanced breast cancer can improve the radicality for a subset of patients, but some patients suffer from severe adverse drug reactions without any benefit. To establish a method for predicting responses to docetaxel, we analyzed gene expression profiles of biopsy materials from 29 advanced breast cancers using a cDNA microarray consisting of 36,864 genes or ESTs, after enrichment of cancer cell population by laser microbeam microdissection. Analyzing eight PR (partial response) patients and twelve patients with SD (stable disease) or PD (progressive disease) response, we identified dozens of genes that were expressed differently between the 'responder (PR)' and 'nonresponder (SD or PD)' groups. We further selected the nine 'predictive' genes showing the most significant differences and established a numerical prediction scoring system that clearly separated the responder group from the non-responder group. This system accurately predicted the drug responses of all of nine additional test cases that were reserved from the original 29 cases. Moreover, we developed a quantitative PCR-based prediction system that could be feasible for routine clinical use. Our results suggest that the sensitivity of an advanced breast cancer to the neoadjuvant chemotherapy with docetaxel could be predicted by expression patterns in this set of genes.",
keywords = "Breast cancer, Docetaxel, Gene expression profile, Microarray, Neoadjuvant chemotherapy, Prediction",
author = "Hitoshi Zembutsu and Yasuyo Suzuki and Aya Sasaki and Tatsuhiko Tsunoda and Minoru Okazaki and Masataka Yoshimoto and Tadashi Hasegawa and Koichi Hirata and Yusuke Nakamura",
year = "2009",
doi = "10.3892/ijo_00000159",
language = "English",
volume = "34",
pages = "361--370",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling

AU - Zembutsu, Hitoshi

AU - Suzuki, Yasuyo

AU - Sasaki, Aya

AU - Tsunoda, Tatsuhiko

AU - Okazaki, Minoru

AU - Yoshimoto, Masataka

AU - Hasegawa, Tadashi

AU - Hirata, Koichi

AU - Nakamura, Yusuke

PY - 2009

Y1 - 2009

N2 - Neoadjuvant chemotherapy with docetaxel for advanced breast cancer can improve the radicality for a subset of patients, but some patients suffer from severe adverse drug reactions without any benefit. To establish a method for predicting responses to docetaxel, we analyzed gene expression profiles of biopsy materials from 29 advanced breast cancers using a cDNA microarray consisting of 36,864 genes or ESTs, after enrichment of cancer cell population by laser microbeam microdissection. Analyzing eight PR (partial response) patients and twelve patients with SD (stable disease) or PD (progressive disease) response, we identified dozens of genes that were expressed differently between the 'responder (PR)' and 'nonresponder (SD or PD)' groups. We further selected the nine 'predictive' genes showing the most significant differences and established a numerical prediction scoring system that clearly separated the responder group from the non-responder group. This system accurately predicted the drug responses of all of nine additional test cases that were reserved from the original 29 cases. Moreover, we developed a quantitative PCR-based prediction system that could be feasible for routine clinical use. Our results suggest that the sensitivity of an advanced breast cancer to the neoadjuvant chemotherapy with docetaxel could be predicted by expression patterns in this set of genes.

AB - Neoadjuvant chemotherapy with docetaxel for advanced breast cancer can improve the radicality for a subset of patients, but some patients suffer from severe adverse drug reactions without any benefit. To establish a method for predicting responses to docetaxel, we analyzed gene expression profiles of biopsy materials from 29 advanced breast cancers using a cDNA microarray consisting of 36,864 genes or ESTs, after enrichment of cancer cell population by laser microbeam microdissection. Analyzing eight PR (partial response) patients and twelve patients with SD (stable disease) or PD (progressive disease) response, we identified dozens of genes that were expressed differently between the 'responder (PR)' and 'nonresponder (SD or PD)' groups. We further selected the nine 'predictive' genes showing the most significant differences and established a numerical prediction scoring system that clearly separated the responder group from the non-responder group. This system accurately predicted the drug responses of all of nine additional test cases that were reserved from the original 29 cases. Moreover, we developed a quantitative PCR-based prediction system that could be feasible for routine clinical use. Our results suggest that the sensitivity of an advanced breast cancer to the neoadjuvant chemotherapy with docetaxel could be predicted by expression patterns in this set of genes.

KW - Breast cancer

KW - Docetaxel

KW - Gene expression profile

KW - Microarray

KW - Neoadjuvant chemotherapy

KW - Prediction

UR - http://www.scopus.com/inward/record.url?scp=64549130078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549130078&partnerID=8YFLogxK

U2 - 10.3892/ijo_00000159

DO - 10.3892/ijo_00000159

M3 - Article

C2 - 19148470

AN - SCOPUS:64549130078

VL - 34

SP - 361

EP - 370

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -